CRAB Treatment
Carbapenem-Resistant Acinetobacter baumannii: Applying Best Practices in Complex Clinical Scenarios

Released: November 15, 2023

Emily Heil
Emily Heil, PharmD, MS, BCIDP, AAHIVP
Trevor Van Schooneveld
Trevor Van Schooneveld, MD, FSHEA, FACP
Laila Woc-Colburn
Laila Woc-Colburn, MD

Activity

Progress
1
Course Completed

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving carbapenem-resistant Acinetobacter baumannii (CRAB), including:

  • Mechanisms for β-lactam resistance
  • Additional resistance mechanisms and virulence factors
  • 2023 IDSA guidance recommendations for moderate to severe CRAB infections
  • The latest clinical data by antimicrobial therapy/regimen:
    • Sulbactam
    • Meropenem and colistin
    • Carbapenem, sulbactam, and polymyxin B
    • Tetracyclines
    • Cefiderocol
    • Sulbactam/durlobactam and carbapenems